NH company shines light on UV therapy for autoimmune conditions
Started in 2021, Cytokind describes itself as 'the global leader in using UVB light to treat immune disorders and improve survival and the quality of life for patients'

Both Kevin Donovan, the outgoing chief financial officer of Portsmouth-based Bottomline Technologies, and his successor, Rick Booth, were upbeat about the company, despite the its quarterly net loss of $7.8 million, nearly double the $4.3 million loss the company reported in the same quarter of 2014.
Bottomline did report that sales rose 9 percent, to $82 million, in the first quarter, which ended March 31. Subscription and transaction revenue – primarily related to the Bottomline's cloud platform – grew to nearly $43 million, accounting for more than half of the company’s revenue stream.
Much of the company’s loss was due to an $8 million asset write-off, primarily related to recent acquisitions, including Intellinx Ltd., an Israeli cyber fraud and risk management firm that Bottomline acquired in January for $66.7 million.
For the first nine months of the fiscal year, the company posted sales of $245.5 million, a $26.6 million increase, and a net loss of $13 million, or 35 cents a share. That’s an improvement from the first three quarters of the last fiscal year, when the net loss was $17.6 million.
Backlog at the end of March was $147.9 million, up $10.7 million from last year.
This is the company’s last earnings release with Donovan as CFO. He announced his resignation to run a family business – effective at the end of June – on April 30. Donovan joined the company in 1999 and became CFO in 2004.
Booth, his 46-year-old replacement, hails from Sapient, a $1.4 billion technology marketing and consulting company based in Boston that was recently purchase for $3.7 billion by the French advertising company Publicis.
Booth will be paid an annual base salary of $280,000 and is eligible to receive a bonus of up to $160,000 as well as a signing bonus of $20,000 and restricted stock awards of 80,000 shares.
At close Tuesday, the company’s stock was trading at $27.37 a share.